Literature DB >> 3102252

Activation of cytotoxic activity in cultures of bone marrow-derived macrophages by indomethacin.

R Voth, E Storch, K Hüller, H Kirchner.   

Abstract

Indomethacin was tested for its ability to augment the cytotoxic capacity of cultured bone marrow-derived macrophages (M phi) against P815 and YAC-1 tumor cells. M phi were obtained from the bone marrow of C57BL/6 mice precultured for 10-14 days and were virtually 100 percent pure. By addition of indomethacin these cells were activated to kill tumor cells in a 4-h and 18-h Cr-release assay. Since indomethacin is a potent inhibitor of the cyclooxygenase system, M phi were treated with prostaglandin E2. This treatment partially reversed indomethacin-induced cytotoxicity. Addition of other cyclooxygenase inhibitors such as acetyl-salicylic-acid, diclofenac or carprofen also induced cytotoxicity in bone marrow-derived M phi. In all experiments we failed to detect any production of interferon. Addition of anti-interferon did not alter the cytolytic capacities demonstrating that endogenously induced interferon was not relevant in this mechanism. Our data show that cyclooxygenase inhibitors induce cytolytic activity of murine M phi not only against a M phi target but also against YAC-1 cells usually considered to be targets for natural killer cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102252     DOI: 10.1002/eji.1830170125

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Indomethacin-sensitive monocyte killing defect in a child with disseminated atypical mycobacterial disease.

Authors:  D Ridgway; L J Wolff; M Wall; M S Borzy; C H Kirkpatrick
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  In vivo and in vitro induction of natural killer cells by cloned human tumor necrosis factor.

Authors:  R Voth; S Rossol; H Gallati; I Pracht; H P Laubenstein; G Hess; W E Müller; H C Schröder; C Jochum; K H Meyer zum Büschenfelde
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.